Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM) Files An 8-K Regulation FD Disclosure

Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Discloser

From time to time, representatives of Angionetics Inc., (the
Company) a majority-owned subsidiary of Taxus Cardium
Pharmaceuticals Group Inc., (Taxus Cardium) conduct meetings with
investors, analysts and other third parties regarding the Company
in which the Company uses a corporate slide presentation. A copy
of the Companys current corporate slide presentation, dated
January 3, 2017 is attached to this Current Report on Form 8-K as
Exhibit 99.1 (the Presentation).

By filing this Current Report on Form 8-K and furnishing the
information contained herein, the Company makes no admission as
to the materiality of any information in this Current Report that
is required to be disclosed solely by reason of Regulation FD.

The information contained in the Presentation is summary
information that is intended to be considered in the context of
Taxus Cardiums Securities and Exchange Commission (SEC) filings
and other public announcements that the Company may make, by
press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the
information contained in this Current Report, although it may do
so from time to time as its management believes is warranted. Any
such updating may be made through the filing of other Current
Reports or documents with the SEC, through press releases or
through other public disclosure.

In accordance with General Instruction B.2 applicable to a
Current Report on Form 8-K, the information presented in Item
7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall
not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.

Description of Exhibit


Investor Relations Presentation

About Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM)

Taxus Cardium Pharmaceuticals Group, Inc. is a holding company. The Company operates a medical technologies portfolio of investments, which include Angionetics, Inc. (Angionetics), Activation Therapeutics, Inc., To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc. (LifeAgain). Angionetics is focused on the late-stage clinical development and commercialization of Generx (Ad5FGF-4), an angiogenic gene therapy product candidate. Activation Therapeutics, Inc. is focused on the development and commercialization of the Excellagen technology platform, which is a flowable dermal matrix for advanced wound care that has various applications as a delivery platform for small molecule drugs, proteins and biologics. LifeAgain has developed an advanced medical data analytics (ADAPT) technology platform focused on developing various products for the life insurance and healthcare sectors. It has an investment in Healthy Brands Collective, a functional food and nutraceutical company.

Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM) Recent Trading Information

Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM) closed its last trading session up +0.002 at 0.160 with 2,318 shares trading hands.

An ad to help with our costs